Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 15;6(1):e000709.
doi: 10.1136/bmjophth-2021-000709. eCollection 2021.

Economic burden and loss of quality of life from dry eye disease in Canada

Affiliations

Economic burden and loss of quality of life from dry eye disease in Canada

Clara Chan et al. BMJ Open Ophthalmol. .

Abstract

Objective: To describe the direct and indirect cost estimates of dry eye disease (DED), stratified by disease severity, and the impact of DED on quality of life (QoL) in Canadian patients.

Methods and analysis: A prospective, multicentre, observational, cross-sectional study was conducted at six sites across Canada. Eligible patients completed a 20 min survey on demography, general health, disease severity, QoL and direct (resource utilisation and out-of-pocket expenses for the past 3-24 months) and indirect costs (absenteeism and presenteeism based on Work Productivity and Activity Impairment questionnaire responses). Subgroup analyses were performed according to DED severity and presence of Sjögren's syndrome.

Results: Responses from 146 of 151 participants were included in the analysis. DED was rated as moderate or severe by 19.2% and 69.2% of patients, respectively. Total mean annual costs of DED were $C24 331 (Canadian dollars) per patient and increased with patient-reported disease severity. Mean (standard deviation [SD]) indirect costs for mild, moderate and severe disease were $C5961 ($C6275), $C16 525 ($C11 607), and $C25 485 ($C22,879), respectively. Mean (SD) direct costs were $C958 ($C1216), $C1303 ($C1574) and $C2766 ($C7161), respectively. QoL scores were lowest in patients with Sjögren's syndrome (8.2% of cohort) and those with severe DED.

Conclusion: This study provides important insights into the negative impact of DED in a Canadian setting. Severe DED was associated with higher direct and indirect costs and lower QoL compared with those with mild or moderate disease. Increased costs and poorer QoL were also evident for patients with DED plus Sjögren's syndrome versus DED alone.

Keywords: clinical trial; ocular surface.

PubMed Disclaimer

Conflict of interest statement

Competing interests: CC has been a consultant for Alcon, Allergan, Bausch+Lomb, Johnson & Johnson, Labtician, Santen, and Shire* and has received research support from Allergan, Bausch+Lomb and TearLab. SZ has received grant/research support from Shire* and honoraria/consulting fees from Allergan, Labtician, J&J, Santen, and Shire*. VM was a paid consultant to Shire* in connection with this study. JGB was an employee of Shire* at the time of the study and is a current employee of Novartis. CLP has been a consultant for Alcon Canada, Innova Medical, Shire*, Novartis and Bausch+Lomb Canada. *A Takeda company.

Figures

Figure 1
Figure 1
Mean annual costs due to DED. CAD, Canadian dollars; DED, dry eye disease.
Figure 2
Figure 2
Mean annual costs according to patient-reported DED severity. CAD, Canadian dollars; DED, dry eye disease.
Figure 3
Figure 3
Mean annual costs according to Sjögren’s syndrome status. CAD, Canadian dollars.
Figure 4
Figure 4
Average QoL subscale scores. Scores for the 12 VFQ 25 QoL subscales and the total QoL score, based on score ranges of 0–100, with lower scores indicating lower QoL. DED, dry eye disease; QoL, quality of life, VFQ, Visual Function Questionnaire.

Similar articles

Cited by

References

    1. Craig JP, Nichols KK, Akpek EK, et al. . TFOS DEWS II definition and classification report. Ocul Surf 2017;15:276–83. 10.1016/j.jtos.2017.05.008 - DOI - PubMed
    1. Stapleton F, Alves M, Bunya VY, et al. . TFOS DEWS II epidemiology report. Ocul Surf 2017;15:334–65. 10.1016/j.jtos.2017.05.003 - DOI - PubMed
    1. Caffery B, Srinivasan S, Reaume CJ, et al. . Prevalence of dry eye disease in Ontario, Canada: a population-based survey. Ocul Surf 2019;17:526–31. 10.1016/j.jtos.2019.02.011 - DOI - PubMed
    1. Wolffsohn JS, Arita R, Chalmers R, et al. . TFOS DEWS II diagnostic methodology report. Ocul Surf 2017;15:539–74. 10.1016/j.jtos.2017.05.001 - DOI - PubMed
    1. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea 2000;19:644–9. 10.1097/00003226-200009000-00009 - DOI - PubMed